Pembrolizumab Plus Concurrent Chemoradiation Therapy in Patients With Unresectable, Locally Advanced, Stage III Non–Small Cell Lung Cancer: The Phase 2 KEYNOTE-799 Nonrandomized Trial

IMPORTANCE: Administration of pembrolizumab plus concurrent chemoradiation therapy (cCRT) may provide treatment benefit to patients with locally advanced, stage III non–small cell lung cancer (NSCLC). OBJECTIVE: To evaluate treatment outcomes and safety of pembrolizumab plus cCRT in stage III NSCLC....

Descripción completa

Detalles Bibliográficos
Autores principales: Jabbour, Salma K., Lee, Ki Hyeong, Frost, Nikolaj, Breder, Valeriy, Kowalski, Dariusz M., Pollock, Theodore, Levchenko, Evgeny, Reguart, Noemi, Martinez-Marti, Alex, Houghton, Baerin, Paoli, Jean-Baptiste, Safina, Sufia, Park, Keunchil, Komiya, Takefumi, Sanford, Amy, Boolell, Vishal, Liu, Hong, Samkari, Ayman, Keller, Steven M., Reck, Martin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2021
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8446818/
https://www.ncbi.nlm.nih.gov/pubmed/34086039
http://dx.doi.org/10.1001/jamaoncol.2021.2301

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8446818/
https://www.ncbi.nlm.nih.gov/pubmed/34086039
http://dx.doi.org/10.1001/jamaoncol.2021.2301

Ejemplares similares